TEM1657

TEM1657 is a proprietary small molecule drug candidate developed for the treatment of chronic inflammatory diseases, with a primary focus on psoriasis. It acts as an inhibitor of the nuclear factor kappa B (NF-κB) pathway and modulates the Th17/23 axis, both of which are central to immune-mediated inflammation. In preclinical studies, TEM1657 demonstrated greater efficacy than dexamethasone in reducing pro-inflammatory cytokines such as IL-8, IL-6, and TNF-α in human keratinocytes. In animal models of psoriasis, topical and oral administration led to rapid remission of symptoms—including erythema and desquamation—without inducing skin atrophy or other common side effects associated with corticosteroids. The compound has also shown potential for use in other inflammatory conditions such as Crohn’s disease and atopic dermatitis due to its mechanism targeting chronic immune activation[1][2][5][6].